A PHASE 1 CLINICAL TRIAL EVALUATING THE NOVEL SMALL MOLECULE IMMUNO-ONCOLOGY ANTAGONIST SX-682 ALONE AND WITH PEMBROLIZUMAB IN METASTATIC MELANOMA